Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Pr Newswire - Dec 18th, 2024

Ascletis Pharma Inc. announced positive results from a study on diet-induced obese mice, where a combination of ASC47 and semaglutide showed significantly greater weight loss and muscle preservation compared to semaglutide monotherapy. The combination treatment reduced body weight by 36.2% versus 23.1% with semaglutide alone and restored body composition to healthy levels. ASC47, a once-monthly subcutaneously injected THRβ selective agonist, also led to statistically significant improvements in liver enzyme levels and lipid profiles. Interim data from a Phase I study in Australia confirmed ASC47's tolerability up to 90 mg, with no serious adverse events. Ascletis is developing ASC47 for obesity and other metabolic diseases, with clinical trials underway.

Asc47 Semaglutide Obesity Weight Loss

Story submitted by Fairstory

RATING

6.8

Fair Story

Consider it well-founded

The article provides detailed information on the performance and potential of ASC47 in combination with semaglutide for weight loss. It presents data from both preclinical and clinical studies, highlighting the drug's effectiveness and safety profile. However, the article primarily reflects the perspectives and interests of Ascletis Pharma Inc., which may affect the balance and transparency of the information presented.

Accuracy

The article appears to report data accurately with specific figures on weight loss and other health metrics. However, it relies on interim data and preclinical results, which may not fully translate to human outcomes.

Balance

The article predominantly presents one perspective, focusing on the positive results of the ASC47 studies. There is a lack of discussion on potential limitations, challenges, or alternative viewpoints, which affects its balance.

Clarity

The language is mostly clear and technical, suitable for an audience familiar with scientific terms. However, the complex data presentation could be challenging for lay readers to fully understand.

Source quality

The article cites interim data from clinical studies and preclinical trials, though it heavily relies on internal data from Ascletis. It would benefit from more external validation or third-party commentary.

Transparency

The article provides detailed results but lacks disclosure of potential conflicts of interest or affiliations beyond the company itself. It is primarily a press release, which may inherently contain promotional elements.